PT1917267E - Forma cristalina de maleato de asenapina - Google Patents
Forma cristalina de maleato de asenapina Download PDFInfo
- Publication number
- PT1917267E PT1917267E PT06725622T PT06725622T PT1917267E PT 1917267 E PT1917267 E PT 1917267E PT 06725622 T PT06725622 T PT 06725622T PT 06725622 T PT06725622 T PT 06725622T PT 1917267 E PT1917267 E PT 1917267E
- Authority
- PT
- Portugal
- Prior art keywords
- orthorhombic
- asenapine maleate
- monoclinic
- asenapine
- maleate
- Prior art date
Links
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 title description 55
- 229960001615 asenapine maleate Drugs 0.000 title description 53
- 239000013078 crystal Substances 0.000 title description 23
- 239000002245 particle Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- VSWBSWWIRNCQIJ-HUUCEWRRSA-N (S,S)-asenapine Chemical class O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-HUUCEWRRSA-N 0.000 claims description 18
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- -1 (Z) -2-butenedioate 2-methyl-1H-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole Chemical compound 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000000634 powder X-ray diffraction Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 229960005245 asenapine Drugs 0.000 description 12
- 238000000113 differential scanning calorimetry Methods 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 238000002447 crystallographic data Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000001237 Raman spectrum Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000005079 FT-Raman Methods 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102742 | 2005-04-07 | ||
| EP05102969 | 2005-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1917267E true PT1917267E (pt) | 2009-02-04 |
Family
ID=36617328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06112332T PT1710245E (pt) | 2005-04-07 | 2006-04-06 | Forma cristalinade maleato de asenapina |
| PT06725622T PT1917267E (pt) | 2005-04-07 | 2006-04-06 | Forma cristalina de maleato de asenapina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06112332T PT1710245E (pt) | 2005-04-07 | 2006-04-06 | Forma cristalinade maleato de asenapina |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP1917267B1 (es) |
| JP (1) | JP5058151B2 (es) |
| KR (1) | KR101422843B1 (es) |
| AR (1) | AR056306A1 (es) |
| AT (2) | ATE370954T1 (es) |
| AU (1) | AU2006231617B2 (es) |
| BR (1) | BRPI0609741A8 (es) |
| CA (1) | CA2603509C (es) |
| CY (2) | CY1106902T1 (es) |
| DE (2) | DE602006000080T2 (es) |
| DK (2) | DK1917267T3 (es) |
| DO (1) | DOP2006000082A (es) |
| ES (2) | ES2318742T3 (es) |
| GT (1) | GT200600135A (es) |
| HN (1) | HN2006014095A (es) |
| HR (1) | HRP20070429T3 (es) |
| IL (1) | IL186355A (es) |
| MX (1) | MX2007012445A (es) |
| MY (1) | MY137969A (es) |
| NO (1) | NO340520B1 (es) |
| NZ (1) | NZ562124A (es) |
| PE (1) | PE20061311A1 (es) |
| PL (2) | PL1917267T3 (es) |
| PT (2) | PT1710245E (es) |
| RS (1) | RS50532B (es) |
| RU (1) | RU2405786C2 (es) |
| SI (2) | SI1710245T1 (es) |
| SV (1) | SV2006002473A (es) |
| TW (1) | TWI364423B (es) |
| UY (1) | UY29459A1 (es) |
| WO (1) | WO2006106135A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002891A1 (es) * | 2006-10-06 | 2008-04-18 | Organon Nv | Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e |
| AU2010264670A1 (en) * | 2009-06-24 | 2012-01-19 | Merck Sharp & Dohme B.V. | Injectable formulations containing asenapine and method of treatment using same |
| WO2011159903A2 (en) | 2010-06-18 | 2011-12-22 | Dr. Reddy's Laboratories Ltd. | Asenapine maleate |
| WO2012066565A2 (en) * | 2010-11-16 | 2012-05-24 | Cadila Healthcare Limited | Asenapine maleate amorphous and crystalline form and process for preparation thereof |
| EP2468750A1 (en) | 2010-12-13 | 2012-06-27 | Chemo Ibérica, S.A. | Polymorphic forms of asenapine maleate and processes for their preparation |
| WO2012123325A1 (en) | 2011-03-11 | 2012-09-20 | Medichem S.A. | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID |
| ITMI20110734A1 (it) * | 2011-05-02 | 2012-11-03 | Olon Spa | Sali cristallini di asenapina |
| EP2524919A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids |
| EP2524920A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Asenapine Hydrochloride Salt Forms |
| EP2524921A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Salts of Asenapine |
| US9533994B2 (en) | 2011-05-18 | 2017-01-03 | Laboratorios Lesvi S.L. | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution |
| JP6014656B2 (ja) * | 2011-05-18 | 2016-10-25 | ラビラトリオス レスビ エス エレ | 化合物の多形体 |
| WO2013041604A1 (en) | 2011-09-21 | 2013-03-28 | Sandoz Ag | Crystal form of asenapine maleate |
| EP2572703A1 (en) | 2011-09-21 | 2013-03-27 | Hexal AG | Compressed oral dosage form for asenapine maleate |
| US10022445B2 (en) * | 2012-07-26 | 2018-07-17 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
| ITMI20121810A1 (it) | 2012-10-24 | 2014-04-25 | Chemo Iberica Sa | Poliformi di maleato di asenapina e processo per la loro preparazione |
| WO2014090386A1 (en) | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
| WO2014127786A1 (en) | 2013-02-22 | 2014-08-28 | Zentiva, K.S. | Orally disintegrating pharmaceutical composition comprising asenapine |
| US10786520B2 (en) | 2015-09-02 | 2020-09-29 | Eloxx Pharmaceuticals Ltd. | Aminoglycoside derivatives and uses thereof in treating genetic disorders |
| RU2762896C2 (ru) | 2016-12-20 | 2021-12-23 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин |
| RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
| BR112019027037B1 (pt) | 2017-06-26 | 2022-04-05 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| US5763476A (en) * | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| AU2418499A (en) * | 1997-12-19 | 1999-07-12 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
| TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
-
2006
- 2006-04-06 GT GT200600135A patent/GT200600135A/es unknown
- 2006-04-06 AR ARP060101358A patent/AR056306A1/es not_active Application Discontinuation
- 2006-04-06 JP JP2008504776A patent/JP5058151B2/ja active Active
- 2006-04-06 DK DK06725622T patent/DK1917267T3/da active
- 2006-04-06 TW TW095112187A patent/TWI364423B/zh active
- 2006-04-06 SV SV2006002473A patent/SV2006002473A/es unknown
- 2006-04-06 EP EP06725622A patent/EP1917267B1/en active Active
- 2006-04-06 ES ES06725622T patent/ES2318742T3/es active Active
- 2006-04-06 ES ES06112332T patent/ES2293626T3/es active Active
- 2006-04-06 SI SI200630006T patent/SI1710245T1/sl unknown
- 2006-04-06 WO PCT/EP2006/061408 patent/WO2006106135A1/en not_active Ceased
- 2006-04-06 RS RSP-2007/0436A patent/RS50532B/sr unknown
- 2006-04-06 AU AU2006231617A patent/AU2006231617B2/en active Active
- 2006-04-06 PL PL06725622T patent/PL1917267T3/pl unknown
- 2006-04-06 KR KR1020077025428A patent/KR101422843B1/ko active Active
- 2006-04-06 PE PE2006000377A patent/PE20061311A1/es active IP Right Grant
- 2006-04-06 DE DE602006000080T patent/DE602006000080T2/de active Active
- 2006-04-06 HN HN2006014095A patent/HN2006014095A/es unknown
- 2006-04-06 BR BRPI0609741A patent/BRPI0609741A8/pt not_active IP Right Cessation
- 2006-04-06 UY UY29459A patent/UY29459A1/es not_active Application Discontinuation
- 2006-04-06 DK DK06112332T patent/DK1710245T3/da active
- 2006-04-06 SI SI200630190T patent/SI1917267T1/sl unknown
- 2006-04-06 RU RU2007141198/04A patent/RU2405786C2/ru active Protection Beyond IP Right Term
- 2006-04-06 PT PT06112332T patent/PT1710245E/pt unknown
- 2006-04-06 EP EP06112332A patent/EP1710245B1/en active Active
- 2006-04-06 DO DO2006P000082A patent/DOP2006000082A/es unknown
- 2006-04-06 DE DE602006004463T patent/DE602006004463D1/de active Active
- 2006-04-06 MX MX2007012445A patent/MX2007012445A/es active IP Right Grant
- 2006-04-06 PL PL06112332T patent/PL1710245T3/pl unknown
- 2006-04-06 MY MYPI20061554A patent/MY137969A/en unknown
- 2006-04-06 NZ NZ562124A patent/NZ562124A/en unknown
- 2006-04-06 PT PT06725622T patent/PT1917267E/pt unknown
- 2006-04-06 CA CA2603509A patent/CA2603509C/en active Active
- 2006-04-06 AT AT06112332T patent/ATE370954T1/de active
- 2006-04-06 AT AT06725622T patent/ATE418556T1/de active
-
2007
- 2007-09-19 HR HR20070429T patent/HRP20070429T3/xx unknown
- 2007-10-02 CY CY20071101258T patent/CY1106902T1/el unknown
- 2007-10-07 IL IL186355A patent/IL186355A/en active IP Right Grant
- 2007-10-10 NO NO20075142A patent/NO340520B1/no unknown
-
2009
- 2009-01-30 CY CY20091100111T patent/CY1108742T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1917267E (pt) | Forma cristalina de maleato de asenapina | |
| US8022228B2 (en) | Crystal form of asenapine maleate | |
| CN1861604B (zh) | 阿色纳品马来酸盐的晶型 | |
| WO2012123325A1 (en) | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID | |
| IL298518B2 (en) | Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation | |
| US12435036B2 (en) | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine | |
| KR102878525B1 (ko) | 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법 | |
| KR20210008829A (ko) | 디히드로피리미딘 화합물의 고체 형태 및 이의 제조 방법 및 이의 용도 | |
| CN114773211B (zh) | 一种葡甲胺盐的晶型、其制备方法及应用 | |
| EP4177257B1 (en) | Succinate of octahydrothienoquinoline compound, and crystals thereof | |
| CN113166169A (zh) | Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物 | |
| CN116041323B (zh) | Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用 | |
| HK1094799A (en) | Crystal form of asenapine maleate | |
| TW202515553A (zh) | 調節ｉｋｚｆ２之化合物之鹽及固體形式 | |
| HK40057196A (en) | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them | |
| HK1102087A1 (zh) | 一種醫藥化合物的結晶形式 | |
| HK1102087B (en) | Crystalline forms of a pharmaceutical compound | |
| EA029298B1 (ru) | Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона |